Advertisement
"We believe that the publication of the ACCLAIM results, in a journalrenowned for the communication of high-quality peer-reviewed research fromaround the world, is indicative of the exceptional design and execution of thetrial, as well as the important contribution of ACCLAIM in identifying therole of Celacade in the treatment of patients suffering from heart failure,"commented Chris Waddick, President and CEO of Vasogen. "The results publishedin Lancet will help to underpin the recently announced commercial launch ofCelacade in the European Union, where it has already been approved, as well asthe initiation of the ACCLAIM-II trial, which is a confirmatory trial in NYHAClass II patients being planned for the purpose of achieving regulatoryapproval in the United States."
Advertisement
The manuscript detailing the results of Vasogen's phase III ACCLAIM trialof Celacade in patients with chronic heart failure is authored by GuillermoTorre-Amione, Methodist Hospital, Houston, TX; Stefan D Anker, Charite, CampusVirchow-Klinikum, Berlin, Germany; Robert C Bourge, University of Alabama atBirmingham, Birmingham, AL; Wilson S Colucci, Boston University School ofMedicine, Boston, MA; Barry H Greenberg, UCSD Medical Center, San Diego, CA;Per Hildebrandt, Frederiksberg Hospital, Frederiksberg, Denmark; Andre Keren,Hadassah University Hospital, Jerusalem, Israel; Michael Motro, Chaim ShebaMedical Center, Tel-Hashomer, Israel; Lemuel A Moye, University of TexasHealth Science Center, Houston, TX; Jan Erik Otterstad, Hospital of Vestfold,Toensberg, Norway; Craig M Pratt, Methodist Hospital, Houston, TX; PiotrPonikowski, Military Hospital, Wroclaw, Poland; Jean Lucien Rouleau, Facultyof Medicine, Universite de Montreal, Montreal, PQ; Francois Sestier, HotelDieu du CHUM, Center de Recherche, Montreal, PQ; Bernhard R Winkelmann,Kardiologische Gemeinschaftspraxis, Frankfurt, Germany; and James B Young, TheCleveland Clinic, Cleveland, OH.
The Lancet's coverage is international in focus and extends to all aspectsof human health. It aims to publish the best original primary research papers,and review articles of the highest standard. The Lancet is stringently editedand peer-reviewed to ensure the scientific merit and clinical relevance of itsdiverse content. Drawing on an international network of advisers andcontributors, The Lancet meets the needs of physicians by adding to theirclinical knowledge and alerting them to current issues affecting the practiceof medicine worldwide.
About Vasogen:
Vasogen is a biotechnology company engaged in the research and commercialdevelopment of therapies designed to target the destructive inflammatoryprocess associated with the development and progression of cardiovascular andneurodegenerative disorders. The Company's lead product, the Celacade(TM)System, is designed to activate the immune response to apoptosis - animportant physiological process that regulates inflammation. Celacade hasreceived European regulatory approval under the CE Mark for chronic heartfailure and is being marketed in the EU by Grupo Ferrer Internacional, S.A.Celacade is also in late-stage clinical development for the treatment ofchronic heart failure in the United States. Vasogen is also developing a newclass of drugs for the treatment of certain neuro-inflammatory di
